TFL Gallery / t-ae-incidence

AET03 · Table

Incidence of Treatment Emergent Adverse Events by Treatment Group

The reference report's Table 14-5.01: subjects, percentages and event counts per system organ class and preferred term, with Fisher's exact test of placebo against each active arm.

Slug
t-ae-incidence
Regulatory ID
AET03
Type
Table
E3 position
§14.3.1
Status
evidenced
Current iteration
v007
Datasets
adae 4ffe4e4, adsl b022f78
Evidence
25/25 passing
Requirements
DSP-AEI-001 DSP-AEI-002 DSP-AEI-003 DSP-AEI-004 DSP-ALL-001 DSP-ALL-002 DSP-INTXT-001 DSP-INTXT-002 DSP-INTXT-003 DSP-REF-001 DSP-REF-002 DSP-REF-003 DSP-REF-004 STD-GATE-001 STD-GATE-002 STD-GATE-003 STD-GATE-004 STD-GATE-005 STD-MODEL-001 STD-MODEL-002 STD-MODEL-003 STD-MODEL-004 STD-MODEL-005 STD-SRC-001 STD-SRC-002
Used in
Study model
Safety Analysis Set SAFFL · grouped by TRT01A
Specification
7 iterations
Environment
R 4.3.3 Darwin 23.6.0
Bound by
No text block binds it
Values
No value is sourced from it
Inputs
Function
Outputs

Generated by the same pipeline run that wrote the ARD and the HTML above, from the same rendered cells; the short hash is the manifest's record of the file.

t-ae-incidence · post_text variant · study CDISCPILOT01 · data cut-off 2014-07-01

Incidence of Treatment Emergent Adverse Events by Treatment Group
Study CDISCPILOT01 — Safety Analysis Set
Placebo (N=86) Xanomeline Low Dose (N=84) Xanomeline High Dose (N=84) Placebo vs. Low Dose Placebo vs. High Dose
ANY BODY SYSTEM 65 (75.6%) [281] 77 (91.7%) [412] 76 (90.5%) [433] 0.007* 0.014*
CARDIAC DISORDERS 12 (14.0%) [26] 13 (15.5%) [30] 15 (17.9%) [30] 0.831 0.534
   SINUS BRADYCARDIA 2 (2.3%) [2] 7 (8.3%) [10] 8 (9.5%) [12] 0.097* 0.056*
   MYOCARDIAL INFARCTION 4 (4.7%) [4] 2 (2.4%) [4] 4 (4.8%) [8] 0.682 >0.99
   ATRIAL FIBRILLATION 1 (1.2%) [1] 1 (1.2%) [1] 3 (3.6%) [5] >0.99 0.365
   ATRIAL FLUTTER 0 1 (1.2%) [1] 1 (1.2%) [2] 0.494 0.494
   CARDIAC DISORDER 0 0 1 (1.2%) [1] 0.494
   SUPRAVENTRICULAR EXTRASYSTOLES 1 (1.2%) [2] 1 (1.2%) [2] 1 (1.2%) [1] >0.99 >0.99
   VENTRICULAR EXTRASYSTOLES 0 2 (2.4%) [4] 1 (1.2%) [1] 0.243 0.494
   ATRIAL HYPERTROPHY 1 (1.2%) [2] 0 0 >0.99 >0.99
   ATRIOVENTRICULAR BLOCK FIRST DEGREE 1 (1.2%) [1] 1 (1.2%) [1] 0 >0.99 >0.99
   ATRIOVENTRICULAR BLOCK SECOND DEGREE 1 (1.2%) [1] 0 0 >0.99 >0.99
   BRADYCARDIA 1 (1.2%) [4] 0 0 >0.99 >0.99
   BUNDLE BRANCH BLOCK LEFT 1 (1.2%) [1] 0 0 >0.99 >0.99
   BUNDLE BRANCH BLOCK RIGHT 1 (1.2%) [2] 1 (1.2%) [1] 0 >0.99 >0.99
   CARDIAC FAILURE CONGESTIVE 1 (1.2%) [1] 0 0 >0.99 >0.99
   PALPITATIONS 0 2 (2.4%) [2] 0 0.243
   SINUS ARRHYTHMIA 1 (1.2%) [2] 0 0 >0.99 >0.99
   SUPRAVENTRICULAR TACHYCARDIA 0 1 (1.2%) [2] 0 0.494
   TACHYCARDIA 1 (1.2%) [2] 0 0 >0.99 >0.99
   VENTRICULAR HYPERTROPHY 1 (1.2%) [1] 0 0 >0.99 >0.99
   WOLFF-PARKINSON-WHITE SYNDROME 0 1 (1.2%) [2] 0 0.494
CONGENITAL, FAMILIAL AND GENETIC DISORDERS 0 1 (1.2%) [1] 2 (2.4%) [2] 0.494 0.243
   VENTRICULAR SEPTAL DEFECT 0 1 (1.2%) [1] 2 (2.4%) [2] 0.494 0.243
EAR AND LABYRINTH DISORDERS 1 (1.2%) [2] 2 (2.4%) [2] 1 (1.2%) [1] 0.618 >0.99
   VERTIGO 0 1 (1.2%) [1] 1 (1.2%) [1] 0.494 0.494
   CERUMEN IMPACTION 0 1 (1.2%) [1] 0 0.494
   EAR PAIN 1 (1.2%) [2] 0 0 >0.99 >0.99
EYE DISORDERS 2 (2.3%) [5] 2 (2.4%) [2] 1 (1.2%) [2] >0.99 >0.99
   VISION BLURRED 0 1 (1.2%) [1] 1 (1.2%) [2] 0.494 0.494
   CONJUNCTIVAL HAEMORRHAGE 0 1 (1.2%) [1] 0 0.494
   CONJUNCTIVITIS 1 (1.2%) [2] 0 0 >0.99 >0.99
   EYE ALLERGY 1 (1.2%) [1] 0 0 >0.99 >0.99
   EYE PRURITUS 1 (1.2%) [1] 0 0 >0.99 >0.99
   EYE SWELLING 1 (1.2%) [1] 0 0 >0.99 >0.99
GASTROINTESTINAL DISORDERS 17 (19.8%) [26] 14 (16.7%) [22] 20 (23.8%) [36] 0.692 0.58
   VOMITING 3 (3.5%) [3] 3 (3.6%) [4] 7 (8.3%) [9] >0.99 0.208
   NAUSEA 3 (3.5%) [3] 3 (3.6%) [5] 6 (7.1%) [13] >0.99 0.326
   DIARRHOEA 9 (10.5%) [10] 4 (4.8%) [5] 4 (4.8%) [4] 0.248 0.248
   SALIVARY HYPERSECRETION 0 0 4 (4.8%) [5] 0.057*
   ABDOMINAL DISCOMFORT 0 0 1 (1.2%) [1] 0.494
   ABDOMINAL PAIN 1 (1.2%) [1] 3 (3.6%) [3] 1 (1.2%) [2] 0.365 >0.99
   GASTROINTESTINAL HAEMORRHAGE 0 0 1 (1.2%) [1] 0.494
   STOMACH DISCOMFORT 0 0 1 (1.2%) [1] 0.494
   CONSTIPATION 1 (1.2%) [1] 0 0 >0.99 >0.99
   DYSPEPSIA 1 (1.2%) [2] 1 (1.2%) [2] 0 >0.99 >0.99
   DYSPHAGIA 0 1 (1.2%) [1] 0 0.494
   FLATULENCE 1 (1.2%) [2] 0 0 >0.99 >0.99
   GASTROOESOPHAGEAL REFLUX DISEASE 1 (1.2%) [1] 0 0 >0.99 >0.99
   GLOSSITIS 1 (1.2%) [1] 0 0 >0.99 >0.99
   HIATUS HERNIA 1 (1.2%) [2] 0 0 >0.99 >0.99
   RECTAL HAEMORRHAGE 0 1 (1.2%) [2] 0 0.494
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS 21 (24.4%) [46] 47 (56.0%) [118] 40 (47.6%) [124] 0.000* 0.002*
   APPLICATION SITE PRURITUS 6 (7.0%) [10] 22 (26.2%) [32] 22 (26.2%) [35] 0.001* 0.001*
   APPLICATION SITE ERYTHEMA 3 (3.5%) [3] 12 (14.3%) [20] 15 (17.9%) [23] 0.015* 0.002*
   APPLICATION SITE IRRITATION 3 (3.5%) [7] 9 (10.7%) [18] 9 (10.7%) [16] 0.078* 0.078*
   APPLICATION SITE DERMATITIS 5 (5.8%) [9] 9 (10.7%) [15] 7 (8.3%) [12] 0.277 0.563
   APPLICATION SITE VESICLES 1 (1.2%) [2] 4 (4.8%) [5] 6 (7.1%) [6] 0.208 0.062*
   FATIGUE 1 (1.2%) [2] 5 (6.0%) [5] 5 (6.0%) [5] 0.115* 0.115*
   APPLICATION SITE PAIN 0 0 2 (2.4%) [2] 0.243
   APPLICATION SITE PERSPIRATION 0 0 2 (2.4%) [3] 0.243
   APPLICATION SITE SWELLING 0 1 (1.2%) [1] 2 (2.4%) [3] 0.494 0.243
   CHEST DISCOMFORT 0 0 2 (2.4%) [2] 0.243
   CHEST PAIN 0 0 2 (2.4%) [2] 0.243
   MALAISE 0 1 (1.2%) [2] 2 (2.4%) [3] 0.494 0.243
   OEDEMA PERIPHERAL 2 (2.3%) [3] 1 (1.2%) [1] 2 (2.4%) [3] >0.99 >0.99
   APPLICATION SITE DISCHARGE 0 0 1 (1.2%) [1] 0.494
   APPLICATION SITE REACTION 1 (1.2%) [2] 0 1 (1.2%) [1] >0.99 >0.99
   APPLICATION SITE URTICARIA 0 2 (2.4%) [2] 1 (1.2%) [1] 0.243 0.494
   ASTHENIA 1 (1.2%) [2] 0 1 (1.2%) [1] >0.99 >0.99
   CHILLS 1 (1.2%) [3] 1 (1.2%) [2] 1 (1.2%) [1] >0.99 >0.99
   FEELING ABNORMAL 0 0 1 (1.2%) [1] 0.494
   FEELING COLD 0 0 1 (1.2%) [1] 0.494
   PAIN 0 1 (1.2%) [2] 1 (1.2%) [1] 0.494 0.494
   PYREXIA 2 (2.3%) [2] 0 1 (1.2%) [1] 0.497 >0.99
   APPLICATION SITE BLEEDING 0 1 (1.2%) [1] 0 0.494
   APPLICATION SITE DESQUAMATION 0 1 (1.2%) [1] 0 0.494
   APPLICATION SITE DISCOLOURATION 0 1 (1.2%) [1] 0 0.494
   APPLICATION SITE INDURATION 1 (1.2%) [1] 0 0 >0.99 >0.99
   APPLICATION SITE WARMTH 0 1 (1.2%) [2] 0 0.494
   INFLAMMATION 0 1 (1.2%) [1] 0 0.494
   OEDEMA 0 2 (2.4%) [2] 0 0.243
   SECRETION DISCHARGE 0 1 (1.2%) [2] 0 0.494
   SUDDEN DEATH 0 1 (1.2%) [1] 0 0.494
   SWELLING 0 1 (1.2%) [1] 0 0.494
   ULCER 0 1 (1.2%) [1] 0 0.494
HEPATOBILIARY DISORDERS 1 (1.2%) [1] 0 0 >0.99 >0.99
   HYPERBILIRUBINAEMIA 1 (1.2%) [1] 0 0 >0.99 >0.99
IMMUNE SYSTEM DISORDERS 0 1 (1.2%) [2] 0 0.494
   HYPERSENSITIVITY 0 1 (1.2%) [2] 0 0.494
INFECTIONS AND INFESTATIONS 16 (18.6%) [35] 9 (10.7%) [16] 13 (15.5%) [20] 0.194 0.685
   NASOPHARYNGITIS 2 (2.3%) [4] 4 (4.8%) [9] 6 (7.1%) [8] 0.441 0.166
   UPPER RESPIRATORY TRACT INFECTION 6 (7.0%) [12] 1 (1.2%) [2] 3 (3.6%) [5] 0.117* 0.496
   CYSTITIS 1 (1.2%) [1] 0 1 (1.2%) [1] >0.99 >0.99
   HORDEOLUM 0 0 1 (1.2%) [1] 0.494
   INFLUENZA 1 (1.2%) [2] 1 (1.2%) [1] 1 (1.2%) [1] >0.99 >0.99
   LOWER RESPIRATORY TRACT INFECTION 0 0 1 (1.2%) [2] 0.494
   RHINITIS 0 0 1 (1.2%) [1] 0.494
   URINARY TRACT INFECTION 2 (2.3%) [4] 0 1 (1.2%) [1] 0.497 >0.99
   BRONCHITIS 1 (1.2%) [1] 0 0 >0.99 >0.99
   CELLULITIS 0 1 (1.2%) [1] 0 0.494
   CERVICITIS 1 (1.2%) [2] 0 0 >0.99 >0.99
   EAR INFECTION 2 (2.3%) [4] 0 0 0.497 0.497
   GASTROENTERITIS VIRAL 1 (1.2%) [1] 0 0 >0.99 >0.99
   LOCALISED INFECTION 1 (1.2%) [2] 0 0 >0.99 >0.99
   PNEUMONIA 0 1 (1.2%) [2] 0 0.494
   VAGINAL MYCOSIS 1 (1.2%) [2] 0 0 >0.99 >0.99
   VIRAL INFECTION 0 1 (1.2%) [1] 0 0.494
INJURY, POISONING AND PROCEDURAL COMPLICATIONS 4 (4.7%) [9] 5 (6.0%) [12] 5 (6.0%) [8] 0.745 0.745
   CONTUSION 1 (1.2%) [1] 1 (1.2%) [3] 2 (2.4%) [3] >0.99 0.618
   HIP FRACTURE 1 (1.2%) [2] 0 2 (2.4%) [2] >0.99 0.618
   EXCORIATION 2 (2.3%) [3] 1 (1.2%) [2] 1 (1.2%) [1] >0.99 >0.99
   FACIAL BONES FRACTURE 0 0 1 (1.2%) [1] 0.494
   FALL 1 (1.2%) [2] 2 (2.4%) [2] 1 (1.2%) [1] 0.618 >0.99
   JOINT DISLOCATION 0 1 (1.2%) [1] 0 0.494
   SKIN LACERATION 1 (1.2%) [1] 2 (2.4%) [2] 0 0.618 >0.99
   WOUND 0 1 (1.2%) [2] 0 0.494
INVESTIGATIONS 10 (11.6%) [19] 6 (7.1%) [7] 6 (7.1%) [8] 0.432 0.432
   BIOPSY 0 0 1 (1.2%) [1] 0.494
   BIOPSY PROSTATE 0 0 1 (1.2%) [1] 0.494
   BLOOD CHOLESTEROL INCREASED 0 0 1 (1.2%) [1] 0.494
   BLOOD GLUCOSE INCREASED 0 1 (1.2%) [1] 1 (1.2%) [2] 0.494 0.494
   ELECTROCARDIOGRAM T WAVE INVERSION 2 (2.3%) [3] 1 (1.2%) [1] 1 (1.2%) [1] >0.99 >0.99
   WEIGHT DECREASED 0 0 1 (1.2%) [2] 0.494
   BLOOD ALKALINE PHOSPHATASE INCREASED 1 (1.2%) [1] 0 0 >0.99 >0.99
   BLOOD CREATINE PHOSPHOKINASE INCREASED 1 (1.2%) [2] 0 0 >0.99 >0.99
   BLOOD URINE PRESENT 1 (1.2%) [1] 0 0 >0.99 >0.99
   BODY TEMPERATURE INCREASED 0 1 (1.2%) [1] 0 0.494
   CYSTOSCOPY 1 (1.2%) [1] 0 0 >0.99 >0.99
   ELECTROCARDIOGRAM ST SEGMENT DEPRESSION 4 (4.7%) [4] 1 (1.2%) [2] 0 0.368 0.121*
   ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED 1 (1.2%) [1] 1 (1.2%) [1] 0 >0.99 >0.99
   HEART RATE INCREASED 1 (1.2%) [2] 0 0 >0.99 >0.99
   HEART RATE IRREGULAR 1 (1.2%) [4] 0 0 >0.99 >0.99
   NASAL MUCOSA BIOPSY 0 1 (1.2%) [1] 0 0.494
METABOLISM AND NUTRITION DISORDERS 6 (7.0%) [8] 1 (1.2%) [1] 2 (2.4%) [4] 0.117* 0.278
   DECREASED APPETITE 1 (1.2%) [2] 0 1 (1.2%) [2] >0.99 >0.99
   INCREASED APPETITE 1 (1.2%) [2] 0 1 (1.2%) [2] >0.99 >0.99
   DEHYDRATION 1 (1.2%) [1] 0 0 >0.99 >0.99
   DIABETES MELLITUS 1 (1.2%) [1] 0 0 >0.99 >0.99
   FOOD CRAVING 1 (1.2%) [1] 1 (1.2%) [1] 0 >0.99 >0.99
   HYPONATRAEMIA 1 (1.2%) [1] 0 0 >0.99 >0.99
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS 4 (4.7%) [6] 7 (8.3%) [10] 7 (8.3%) [10] 0.367 0.367
   BACK PAIN 1 (1.2%) [2] 1 (1.2%) [1] 3 (3.6%) [4] >0.99 0.365
   ARTHRALGIA 1 (1.2%) [1] 2 (2.4%) [4] 1 (1.2%) [1] 0.618 >0.99
   ARTHRITIS 0 0 1 (1.2%) [1] 0.494
   FLANK PAIN 0 0 1 (1.2%) [1] 0.494
   MUSCLE SPASMS 0 1 (1.2%) [1] 1 (1.2%) [2] 0.494 0.494
   MYALGIA 0 0 1 (1.2%) [1] 0.494
   MUSCULAR WEAKNESS 0 1 (1.2%) [2] 0 0.494
   PAIN IN EXTREMITY 1 (1.2%) [1] 0 0 >0.99 >0.99
   SHOULDER PAIN 1 (1.2%) [2] 2 (2.4%) [2] 0 0.618 >0.99
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) 0 2 (2.4%) [3] 1 (1.2%) [1] 0.243 0.494
   PROSTATE CANCER 0 0 1 (1.2%) [1] 0.494
   COLON CANCER 0 1 (1.2%) [1] 0 0.494
   MALIGNANT FIBROUS HISTIOCYTOMA 0 1 (1.2%) [2] 0 0.494
NERVOUS SYSTEM DISORDERS 8 (9.3%) [11] 20 (23.8%) [40] 25 (29.8%) [41] 0.013* 0.001*
   DIZZINESS 2 (2.3%) [3] 8 (9.5%) [13] 11 (13.1%) [15] 0.056* 0.009*
   HEADACHE 3 (3.5%) [3] 3 (3.6%) [4] 5 (6.0%) [8] >0.99 0.493
   SYNCOPE 0 4 (4.8%) [6] 3 (3.6%) [4] 0.057* 0.118*
   BURNING SENSATION 0 0 2 (2.4%) [2] 0.243
   AMNESIA 0 0 1 (1.2%) [2] 0.494
   COGNITIVE DISORDER 0 0 1 (1.2%) [1] 0.494
   HYPERSOMNIA 0 0 1 (1.2%) [1] 0.494
   LETHARGY 0 1 (1.2%) [1] 1 (1.2%) [1] 0.494 0.494
   PARAESTHESIA 0 0 1 (1.2%) [1] 0.494
   PAROSMIA 0 0 1 (1.2%) [2] 0.494
   PARTIAL SEIZURES WITH SECONDARY GENERALISATION 0 0 1 (1.2%) [1] 0.494
   SOMNOLENCE 2 (2.3%) [3] 3 (3.6%) [5] 1 (1.2%) [1] 0.68 >0.99
   SYNCOPE VASOVAGAL 0 0 1 (1.2%) [1] 0.494
   TRANSIENT ISCHAEMIC ATTACK 0 2 (2.4%) [3] 1 (1.2%) [1] 0.243 0.494
   BALANCE DISORDER 0 1 (1.2%) [3] 0 0.494
   COMPLEX PARTIAL SEIZURES 0 1 (1.2%) [1] 0 0.494
   COORDINATION ABNORMAL 0 1 (1.2%) [1] 0 0.494
   HEMIANOPIA HOMONYMOUS 0 1 (1.2%) [1] 0 0.494
   PARAESTHESIA ORAL 0 1 (1.2%) [1] 0 0.494
   PARKINSON'S DISEASE 1 (1.2%) [1] 0 0 >0.99 >0.99
   PSYCHOMOTOR HYPERACTIVITY 1 (1.2%) [1] 0 0 >0.99 >0.99
   STUPOR 0 1 (1.2%) [1] 0 0.494
PSYCHIATRIC DISORDERS 10 (11.6%) [12] 10 (11.9%) [14] 8 (9.5%) [11] >0.99 0.804
   INSOMNIA 2 (2.3%) [3] 0 2 (2.4%) [2] 0.497 >0.99
   AGITATION 2 (2.3%) [2] 2 (2.4%) [2] 1 (1.2%) [1] >0.99 >0.99
   CONFUSIONAL STATE 2 (2.3%) [2] 3 (3.6%) [3] 1 (1.2%) [1] 0.68 >0.99
   DELIRIUM 0 0 1 (1.2%) [1] 0.494
   DELUSION 1 (1.2%) [1] 0 1 (1.2%) [1] >0.99 >0.99
   HALLUCINATION 0 0 1 (1.2%) [1] 0.494
   HALLUCINATION, VISUAL 0 0 1 (1.2%) [1] 0.494
   LIBIDO DECREASED 0 0 1 (1.2%) [1] 0.494
   LISTLESS 0 0 1 (1.2%) [1] 0.494
   NIGHTMARE 0 0 1 (1.2%) [1] 0.494
   ANXIETY 0 3 (3.6%) [4] 0 0.118*
   COMPLETED SUICIDE 1 (1.2%) [1] 0 0 >0.99 >0.99
   DEPRESSED MOOD 0 1 (1.2%) [2] 0 0.494
   DISORIENTATION 1 (1.2%) [1] 0 0 >0.99 >0.99
   IRRITABILITY 1 (1.2%) [2] 1 (1.2%) [1] 0 >0.99 >0.99
   RESTLESSNESS 0 1 (1.2%) [2] 0 0.494
RENAL AND URINARY DISORDERS 4 (4.7%) [5] 3 (3.6%) [3] 3 (3.6%) [4] >0.99 >0.99
   CALCULUS URETHRAL 0 0 1 (1.2%) [1] 0.494
   MICTURITION URGENCY 1 (1.2%) [1] 1 (1.2%) [1] 1 (1.2%) [2] >0.99 >0.99
   NEPHROLITHIASIS 1 (1.2%) [1] 0 1 (1.2%) [1] >0.99 >0.99
   DYSURIA 1 (1.2%) [1] 1 (1.2%) [1] 0 >0.99 >0.99
   INCONTINENCE 0 1 (1.2%) [1] 0 0.494
   POLLAKIURIA 1 (1.2%) [2] 0 0 >0.99 >0.99
REPRODUCTIVE SYSTEM AND BREAST DISORDERS 2 (2.3%) [4] 0 1 (1.2%) [1] 0.497 >0.99
   BENIGN PROSTATIC HYPERPLASIA 1 (1.2%) [2] 0 1 (1.2%) [1] >0.99 >0.99
   PELVIC PAIN 1 (1.2%) [2] 0 0 >0.99 >0.99
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS 8 (9.3%) [12] 9 (10.7%) [14] 10 (11.9%) [22] 0.803 0.626
   COUGH 1 (1.2%) [1] 5 (6.0%) [7] 5 (6.0%) [7] 0.115* 0.115*
   NASAL CONGESTION 3 (3.5%) [3] 1 (1.2%) [1] 3 (3.6%) [4] 0.621 >0.99
   EPISTAXIS 0 1 (1.2%) [1] 2 (2.4%) [2] 0.494 0.243
   ALLERGIC GRANULOMATOUS ANGIITIS 0 0 1 (1.2%) [1] 0.494
   DYSPNOEA 1 (1.2%) [1] 1 (1.2%) [1] 1 (1.2%) [1] >0.99 >0.99
   PHARYNGEAL ERYTHEMA 0 0 1 (1.2%) [2] 0.494
   PHARYNGOLARYNGEAL PAIN 0 1 (1.2%) [1] 1 (1.2%) [1] 0.494 0.494
   PRODUCTIVE COUGH 0 0 1 (1.2%) [1] 0.494
   RESPIRATORY TRACT CONGESTION 0 0 1 (1.2%) [1] 0.494
   RHINORRHOEA 0 1 (1.2%) [2] 1 (1.2%) [2] 0.494 0.494
   DYSPHONIA 0 1 (1.2%) [1] 0 0.494
   EMPHYSEMA 1 (1.2%) [1] 0 0 >0.99 >0.99
   HAEMOPTYSIS 1 (1.2%) [2] 0 0 >0.99 >0.99
   POSTNASAL DRIP 1 (1.2%) [2] 0 0 >0.99 >0.99
   RALES 1 (1.2%) [2] 0 0 >0.99 >0.99
SKIN AND SUBCUTANEOUS TISSUE DISORDERS 20 (23.3%) [45] 39 (46.4%) [111] 40 (47.6%) [104] 0.002* 0.001*
   PRURITUS 8 (9.3%) [11] 21 (25.0%) [31] 26 (31.0%) [38] 0.008* 0.000*
   ERYTHEMA 8 (9.3%) [12] 14 (16.7%) [22] 14 (16.7%) [22] 0.175 0.175
   RASH 5 (5.8%) [9] 13 (15.5%) [18] 9 (10.7%) [15] 0.048* 0.277
   HYPERHIDROSIS 2 (2.3%) [2] 4 (4.8%) [5] 8 (9.5%) [10] 0.441 0.056*
   SKIN IRRITATION 3 (3.5%) [4] 6 (7.1%) [13] 5 (6.0%) [8] 0.326 0.493
   RASH PRURITIC 0 1 (1.2%) [2] 2 (2.4%) [3] 0.494 0.243
   ACTINIC KERATOSIS 0 0 1 (1.2%) [1] 0.494
   BLISTER 0 5 (6.0%) [8] 1 (1.2%) [2] 0.028* 0.494
   PRURITUS GENERALISED 0 1 (1.2%) [4] 1 (1.2%) [1] 0.494 0.494
   RASH MACULO-PAPULAR 0 0 1 (1.2%) [1] 0.494
   SKIN ODOUR ABNORMAL 0 0 1 (1.2%) [1] 0.494
   URTICARIA 0 1 (1.2%) [3] 1 (1.2%) [2] 0.494 0.494
   ALOPECIA 1 (1.2%) [1] 0 0 >0.99 >0.99
   COLD SWEAT 1 (1.2%) [3] 0 0 >0.99 >0.99
   DERMATITIS CONTACT 0 1 (1.2%) [2] 0 0.494
   DRUG ERUPTION 1 (1.2%) [1] 0 0 >0.99 >0.99
   RASH ERYTHEMATOUS 0 1 (1.2%) [1] 0 0.494
   SKIN EXFOLIATION 0 1 (1.2%) [2] 0 0.494
   SKIN ULCER 1 (1.2%) [2] 0 0 >0.99 >0.99
SOCIAL CIRCUMSTANCES 0 0 1 (1.2%) [1] 0.494
   ALCOHOL USE 0 0 1 (1.2%) [1] 0.494
SURGICAL AND MEDICAL PROCEDURES 2 (2.3%) [2] 1 (1.2%) [1] 2 (2.4%) [2] >0.99 >0.99
   ACROCHORDON EXCISION 0 0 1 (1.2%) [1] 0.494
   SKIN LESION EXCISION 0 0 1 (1.2%) [1] 0.494
   CATARACT OPERATION 1 (1.2%) [1] 1 (1.2%) [1] 0 >0.99 >0.99
   EYE LASER SURGERY 1 (1.2%) [1] 0 0 >0.99 >0.99
VASCULAR DISORDERS 3 (3.5%) [7] 3 (3.6%) [3] 1 (1.2%) [1] >0.99 0.621
   WOUND HAEMORRHAGE 0 0 1 (1.2%) [1] 0.494
   HOT FLUSH 0 1 (1.2%) [1] 0 0.494
   HYPERTENSION 1 (1.2%) [2] 1 (1.2%) [1] 0 >0.99 >0.99
   HYPOTENSION 2 (2.3%) [3] 1 (1.2%) [1] 0 >0.99 0.497
   ORTHOSTATIC HYPOTENSION 1 (1.2%) [2] 0 0 >0.99 >0.99
Treatment-emergent events are those flagged TRTEMFL = 'Y' in the study's ADAE: events that start on or after the start of treatment, as the reference report (Table 14-5.01) defines them. Adverse events are coded using MedDRA.
Subjects are counted once per system organ class and once per preferred term; percentages are based on the number of subjects in the safety population within each treatment group. The bracketed figure is the total number of times an event was recorded.
P-values are Fisher's exact test comparing placebo with each active treatment group on the number of subjects with the event. An asterisk is appended to p-values below 0.15, as in the reference report; a p-value that rounds to 1 prints as >0.99; where neither arm has a subject with the event there is no test and the cell is blank.
System organ classes are in alphabetical order; preferred terms within a class are in descending order of high-dose subjects, then alphabetical — the order the reference report prints.
Four of the 227 p-values the reference report prints differ from this display at the third decimal, each by one thousandth: vomiting (placebo vs high dose, 0.208 here, 0.209 there), salivary hypersecretion (0.057 here, 0.058 there), application site erythema (0.002 here, 0.003 there) and syncope (placebo vs low dose, 0.057 here, 0.058 there). The subject counts agree; R's exact two-sided test gives 0.2085, 0.0575, 0.0025 and 0.0575, and the 2006 program rounded each up. They are recorded and tracked in quality/data/reference-report-agreement.json.
Source: adae, adsl (CDISCPILOT01 ADaM package, phuse-org/phuse-scripts). Data cut-off: 2014-07-01.
open.csr display t-ae-incidence (post_text variant); generated from the committed ARD.

Rendered from outputs/t-ae-incidence/v007/table.html.

Every iteration is kept: outputs/t-ae-incidence/vNNN/ holds the spec snapshot, the ARD, the rendered output, and a manifest recording who regenerated it, why, and from which commit.